Production (Stage)
PDS Biotechnology Corporation
PDSB
$1.69
$0.138.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.64M | 13.76M | 13.87M | 14.56M | 15.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.33M | 36.32M | 39.37M | 39.71M | 43.72M |
| Operating Income | -35.33M | -36.32M | -39.37M | -39.71M | -43.72M |
| Income Before Tax | -37.54M | -38.48M | -41.43M | -41.55M | -45.29M |
| Income Tax Expenses | -2.04M | -869.20K | -869.20K | -869.20K | -1.41M |
| Earnings from Continuing Operations | -35.50 | -37.61 | -40.56 | -40.68 | -43.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.50M | -37.61M | -40.56M | -40.68M | -43.89M |
| EBIT | -35.33M | -36.32M | -39.37M | -39.71M | -43.72M |
| EBITDA | -35.27M | -36.26M | -39.31M | -39.65M | -43.66M |
| EPS Basic | -0.94 | -1.04 | -1.17 | -1.23 | -1.37 |
| Normalized Basic EPS | -0.62 | -0.66 | -0.74 | -0.78 | -0.89 |
| EPS Diluted | -0.94 | -1.04 | -1.17 | -1.23 | -1.37 |
| Normalized Diluted EPS | -0.62 | -0.66 | -0.74 | -0.78 | -0.89 |
| Average Basic Shares Outstanding | 151.51M | 145.80M | 139.98M | 134.08M | 128.19M |
| Average Diluted Shares Outstanding | 151.51M | 145.80M | 139.98M | 134.08M | 128.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |